

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-10. (Cancelled)

11. (New) An anti-IFNAR1 monoclonal antibody that
- a) inhibits the anti-viral activity of a first type I interferon selected from the group consisting of IFN- α 1, IFN- α 2/1, IFN- α 2, IFN- α 5, and IFN- α 8;
 - b) does not inhibit the anti-viral activity of IFN- β .
12. (New) The monoclonal antibody of claim 11 that binds to one or more amino acids *in situ* in the sequence of amino acids 244-249 of IFNAR1 having the amino acid sequence of SEQ ID NO:22.
13. (New) The monoclonal antibody of claim 12, wherein the monoclonal antibody does not bind to one or more amino acids *in situ* in the sequence of amino acids 291-298 of IFNAR1 having the amino acid sequence of SEQ ID NO:22.
14. (New) The monoclonal antibody of claim 12, wherein the monoclonal antibody binds to amino acid 249 of IFNAR1 *in situ* having the amino acid sequence of SEQ ID NO:22.
15. (New) The monoclonal antibody of claim 14, wherein the monoclonal antibody binds to amino acids 291 and 296 of IFNAR1 *in situ* having the amino acid sequence of SEQ ID NO:22.
16. (New) The monoclonal antibody of claim 11, wherein the monoclonal antibody does not bind to one or more amino acids 244-249 of IFNAR1 having the amino acid sequence of SEQ ID NO:22.

17. (New) The monoclonal antibody of claim 16, wherein the monoclonal antibody recognizes a conformational epitope of IFNAR1.
18. (New) The monoclonal antibody of claim 11, wherein the first type I interferon is IFN- α 8.
19. (New) The monoclonal antibody of claim 11, wherein the monoclonal antibody inhibits the anti-viral activity of type I interferons IFN- α 2, IFN- α 5, and IFN- α 8.
20. (New) The monoclonal antibody of claim 11, wherein the monoclonal antibody exhibits an EC₅₀ of up to or about 1 μ g/ml against the anti-viral activity of the first type I interferon.
21. (New) The monoclonal antibody of claim 11, wherein the monoclonal antibody exhibits an EC₅₀ of up to or about 10 μ g/ml against the anti-viral activity of the first type I interferon.
22. (New) The monoclonal antibody of claim 11, wherein the monoclonal antibody exhibits an EC₅₀ of up to or about 20 μ g/ml against the anti-viral activity of the first type I interferon.
23. (New) The monoclonal antibody of claim 11, wherein the monoclonal antibody exhibits an EC₅₀ of up to or about 50 μ g/ml against the anti-viral activity of the first type I interferon.
24. (New) The monoclonal anti-IFNAR1 antibody of claim 11 having the heavy chain CDRs of the monoclonal antibody 2E1, ATCC Deposit No. HB12133.
25. (New) The monoclonal antibody of claim 11 having the heavy chain CDRs of the monoclonal antibody 4A7, ATCC Deposit No. HB12132.
26. (New) The monoclonal antibody of claim 11 having the heavy chain CDRs of the monoclonal antibody 5H8, ATCC Deposit No. HB12129.

27. (New) The monoclonal antibody of any of claims 24-26 which is humanized.
28. (New) The monoclonal antibody of any of claims 24-26 which is synthetic.
29. (New) A kit for diagnostic assays comprising a monoclonal antibody of claim 11.
30. (New) A kit of claim 29, wherein the monoclonal antibody is labeled.
31. (New) A kit for diagnostic assays comprising a monoclonal antibody of claim 15.
32. (New) A kit of claim 31, wherein the monoclonal antibody is labeled.
33. (New) A method for treatment of an immune-mediated or autoimmune disorder comprising administering a therapeutically effective amount of an anti-IFNAR1 monoclonal antibody of claim 27 to a mammal.
34. (New) The method of claim 33, wherein the autoimmune disorder is selected from the group consisting of insulin-dependent diabetes mellitus, noninsulin-dependent diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, and combinations thereof.
35. (New) The method of claim 34, wherein the autoimmune disorder is insulin-dependent diabetes mellitus.
36. (New) The method of claim 35, wherein the immune-mediated disorder is graft rejection or graft versus host disease.
37. (New) The method of claim 36, wherein the anti-IFNAR1 monoclonal antibody is administered prior to transplantation surgery.

38. (New) The method of claim 36, wherein the anti-IFNAR1 monoclonal antibody is administered post-transplant surgery.
39. (New) A method for detecting IFNAR1 comprising:
- a) contacting an isolated cell with an anti-IFNAR1 monoclonal antibody of claim 11; and
 - b) detecting IFNAR1 expression in said cell.
40. (New) The method of claim 39, wherein the isolated cell is in cell culture.
41. (New) The method of claim 39, wherein the isolated cell is in a tissue.
42. (New) The method of claim 39, wherein the detecting IFNAR1 expression determines IFNAR1 distribution or density in a cell population.
43. (New) A hybridoma cell line producing an anti-IFNAR1 monoclonal antibody of claim 11.
44. (New) The hybridoma cell line of claim 43, wherein the hybridoma cell line is ATCC HB 12132.
45. (New) The hybridoma cell line of claim 43, wherein the hybridoma cell line is ATCC HB 12133.
46. (New) The hybridoma cell line of claim 43, wherein the hybridoma cell line is ATCC HB 12129.
47. (New) The monoclonal antibody produced by a hybridoma having Deposit No. ATCC HB 12129.

48. (New) The monoclonal antibody produced by a hybridoma having Deposit No. ATCC HB 12133.

49. (New) The monoclonal antibody produced by a hybridoma having Deposit No. ATCC HB 12132.